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The cytokine erythropoietin (Epo) is an essential factor promoting the survival, proliferation, and differentiation of erythroid progenitor
cells. Epo expression and the initial phase of definitive erythropoietic differentiation in the fetal liver (E9–E12) are compromised in mouse
embryos lacking the retinoic acid receptor RXRa. Our previous work demonstrated that the Epo gene is a direct target of retinoic acid action,
via a retinoic acid receptor binding site in the Epo gene enhancer. However, Epo expression and erythropoietic differentiation become
normalized in RXRa mutants from E12. In this study, we have investigated the molecular mechanisms underlying the transition in Epo gene
regulation from RXRa-dependence to RXRa-independence. We find that three independent regulatory components are required for high
level Epo expression in the early fetal liver: ligand-activated retinoic acid receptors, the hypoxia-regulated factor HIF1, and GATA factors. By
E11.5, the fetal liver is no longer hypoxic, and retinoic acid signaling is no longer active; Epo expression from E11.5 onward is enhancer-
independent, and is driven instead by basal promoter elements that provide a sufficient level of expression to support further erythropoietic
differentiation.
D 2005 Elsevier Inc. All rights reserved.
Keywords: Erythropoiesis; Erythropoietin; Fetal liver; Retinoic acid; Hypoxia; HNF4Introduction
The generation of red blood cells (erythropoiesis) is an
essential process in vertebrate embryogenesis to progress
from diffusion-limited growth to circulatory system-medi-
ated growth. Erythropoiesis involves the commitment of a
pluriopotent hematopoietic stem cell to the erythroid
lineage, followed by progression through erythroid progen-
itor and several erythroblast stages, and ultimately culmi-
nating in the terminally differentiated erythrocyte. In mouse0012-1606/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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E-mail address: sucov@usc.edu (H.M. Sucov).embryos, erythropoiesis begins in the yolk sac around
embryonic day 7.5 (E7.5), concurrent with the initiation of
heart contractions. This phase is called primitive erythro-
poiesis, and concludes around E11.5 with the establishment
of definitive erythropoiesis in the embryo proper, although
primitive (yolk sac-derived) erythrocytes persist for another
2 or 3 days. Definitive erythropoiesis initiates in the fetal
liver around E9.5 (Houssaint, 1981; Palis et al., 1999),
concurrent with the formation of the liver from the hepatic
diverticulum of the caudal foregut, via colonization by
hematopoietic stem cells. In late gestation, definitive
hematopoiesis migrates to the bone marrow where it persists
throughout postnatal life.
The cytokine erythropoietin (Epo), which is primarily
produced by fetal liver hepatocytes and by interstitial cells280 (2005) 59–72
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erythropoiesis. Epo contributes to the survival and prolifer-
ation of erythropoietic progenitor cells in the fetal liver and
is further required for these cells to reach the terminal steps
of definitive erythropoiesis. Thus, erythroid progenitor
populations are reduced in number and no fetal liver-
derived erythroblasts or red blood cells form in Epo/
embryos (Wu et al., 1995). Epo is not required for primitive
erythropoiesis, in that mouse embryos lacking Epo support
(albeit at a reduced level) yolk sac production of red blood
cells. Epo-deficient embryos die of anemia at E13.5, when
the yolk sac-derived red blood cells that sustained develop-
ment from E7.5–E12.5 die out and are not replaced through
definitive erythropoiesis. These embryos show a character-
istic small and pale fetal liver at E12.5 and E13.5, a
consequence of the absence of terminal erythropoietic
differentiation in the liver.
One of the known physiological regulators of Epo
expression is hypoxia (Bunn et al., 1998). A reduced
oxygen level results in the stabilization of the transcription
factor HIF1a (hypoxia-inducible factor 1a) (Semenza,
2001), which heterodimerizes with the hypoxia-independ-
ent subunit HIF1h (also known as ARNT) and binds to a
defined HIF1 response element in the 3V enhancer of the
Epo gene (Pugh et al., 1991; Semenza et al., 1991) to
upregulate expression. In the fetal liver, Epo is expressed
primarily by hepatocytes (Koury et al., 1991), and hypoxia-
regulated expression is conserved in hepatocellular carci-
noma cell lines such as Hep3B and HepG2 (Goldberg et
al., 1987). Adjacent to the HIF1 binding site in the mouse
Epo 3V enhancer is the sequence TGACCTctTGACCC,
which is known as a DR2 element because of the direct
repeat of the hexameric sequence TGACC(C/T) spaced by
two nucleotides. The Epo enhancer DR2 element is
required for full hypoxic regulation of the Epo gene,
although it is not itself responsible for sensing hypoxia
(Blanchard et al., 1992). DR2 elements are known binding
sites for some members of the nuclear receptor family, and
the orphan nuclear receptor HNF4 (hepatocyte nuclear
factor-4) has been considered to be the primary factor
which is responsible for Epo gene regulation through the
DR2 element (Galson et al., 1995). HNF4 is expressed in
the fetal liver and postnatal kidney, both sites of Epo gene
expression, and is expressed in Hep3B and HepG2 cells as
well. Furthermore, forced expression of HNF4 in trans-
fected HeLa cells (which do not normally express HNF4)
supports hypoxic inducibility of an Epo reporter construct.
HNF4 appears to function synergistically with HIF1 on the
Epo enhancer by direct protein–protein interaction and
through the recruitment of transcriptional coactivators
(Bunn et al., 1998).
We have studied the biological function of the retinoic
acid receptor, which is comprised of a heterodimer of
RAR and RXR, both members of the nuclear receptor
family (Evans, 1988). Mouse embryos lacking the RXRa
gene show a completely penetrant fetal liver phenotype atE11.5–E12.5 that is comparable to the fetal liver pheno-
type of Epo-deficient embryos, including a pale appear-
ance, extensive death of erythroid progenitors, and failure
of erythropoietic differentiation (Makita et al., 2001;
Sucov et al., 1994). We demonstrated previously (Makita
et al., 2001) that the Epo enhancer DR2 element is a
direct target of retinoic acid receptor action: Epo mRNA
levels are substantially reduced (at least 10-fold) in the
fetal liver of RXRa/ embryos at E10.25, and are
retinoic acid inducible in wild type embryonic liver tissue
or in primary hepatocyte obtained from wild type embryos
at E10.25; furthermore, the Epo enhancer DR2 element is
a binding site for RXR–RAR heterodimers, and in
transient transfection assays this element confers retinoic
acid responsiveness to a reporter gene, and is required for
RA responsiveness of an Epo promoter/enhancer reporter
gene. Finally, while heterozygotes for RXRa or for Epo
are phenotypically normal, RXRa/Epo double heterozy-
gotes are compromised in fetal liver erythroid differ-
entiation, demonstrating genetic interaction. Thus, retinoic
acid and RA receptors directly regulate Epo gene
expression at the transcriptional level in the fetal liver,
and the phenotype of RXRa mutants represents a
deficiency of Epo expression.
However, the erythropoietic deficiency of RXRa/
embryos is transient. Epo gene expression in the fetal liver
of mutant embryos becomes normalized relative to control
littermates at E12.5, and the fetal liver cellular phenotype of
mutant embryos becomes normalized by E13.5 with
recovery of erythroid progenitor cell proliferation and
differentiation. Thus, while the early phase (E9.5–11.5) of
Epo expression is clearly under retinoic acid control, by
E12.5 the Epo gene is regulated by RXRa-independent
mechanisms. We previously suggested (Makita et al., 2001)
that HNF4 might supplant RAR/RXR function in fetal liver
beginning around E12.5. As noted above, HNF4 and RAR/
RXR bind to the same DR2 element in the Epo gene
enhancer, and transient transfection assays indicated that
HNF4 could compete with RAR/RXR for binding to this
sequence.
In this study, we have identified the transcriptional
components that control Epo gene expression and that are
responsible for the transition from retinoic acid and
RXRa-dependency in the early E9.5–11.5 phase of
definitive erythropoiesis to RXRa-independent control
thereafter. We show that the Epo gene is regulated by
three synergizing factors: RXR/RAR binding to the
enhancer DR2 element, HIF1 binding to the adjacent
hypoxia response element of the enhancer, and GATA
factors which bind to a proximal promoter element. The
early fetal liver contains high levels of RARs, RXRa,
HIF1, and GATA factors, as well as the enzymatic
components needed for RA synthesis, and is hypoxic as
well. Although these conditions change by E12, we find
that HNF4 does not supplant RAR/RXR to mediate Epo
expression. Rather, Epo expression becomes enhancer-
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minimal yet sufficient level to support continuing eryth-
ropoietic differentiation.Materials and methods
Immunoblotting
Nuclei were isolated from triturated fetal liver tissue by
hypotonic lysis and low speed centrifugation and were
extracted with buffer containing 0.5 M KCl as described
(Jiang et al., 1995). 15 Ag of fetal liver nuclear extracts
was used for immunoblotting using standard procedures.
Antibodies used for Western blotting were all from Santa
Cruz.
Quantitative RT-PCR/Real-time PCR
Total RNA was extracted from individual fetal liver
tissue and reverse transcribed using standard conditions. All
samples were analyzed independently by real-time PCR
using an iCycler iQ with SYBR green supermix (Bio-Rad),
and by quantitative PCR as described previously (Makita et
al., 2001) with some modifications. For the latter, equal
amounts of RT product were subjected to PCR amplifica-
tion in the presence of 0.5 ACi [a-32P] dCTP. PCR products
from each cycle between 25 and 32 cycles of amplification
(additional cycles were tested for low abundant or
undetectable transcripts) were separated by polyacrylamide
gel electrophoresis, and the dried gels analyzed by
PhosphoImaging (Molecular Dynamics). 18S ribosomal
RNA was analyzed at each cycle between 16 and 22 cycles
under identical conditions. The amplification efficiency for
each gene was obtained from the plot of relative log cpm
vs. cycle number; the GC content and PCR product length
were considered when the relative abundance was calcu-
lated. The normalized amount of transcript in each sample
was calculated from the amplification efficiency and the
relative cpm incorporated at a cycle number appropriate for
each gene within its linear range of amplification. To
compare transcript levels for a given gene between samples,
PCR products from each sample at the same cycle number
within the linear range were separated on a gel and exposed
to film.
Immunohistochemistry
Pregnant females were subjected to intraperitoneal
injection of 60 mg/kg body weight pimonidazole hydro-
chloride (Hypoxiprobe-1, Chemicon International). 90 min
after injection, embryos were isolated, fixed in 4%
paraformaldehyde, paraffin embedded, and sectioned. After
antigen retrieval by boiling in citrate buffer (pH 6.0),
sections were immunostained with antibodies against
Hypoxyprobe adducts (Chemicon International) or HIF1a(Santa Cruz). Sections were further incubated with biotin-
conjugated secondary antibody, followed by streptavidin
peroxidase/DAB for color development.
Primary hepatocyte culture
Fetal liver tissue was isolated by dissection from
embryos at E12.5 and dissociated by trituration in cold
PBS containing 0.2% BSA, 0.02% EDTA, and 0.03%
sodium azide. Cells were resuspended in DMEM containing
10% FBS, 1.2 mg/ml BSA, 5 Ag/ml insulin, 5 Ag/ml
transferrin, and 105 M linolenic acid, and preplated on
tissue culture plates for 2 h. Non-adherent cells (hepatocytes
and hematopoietic cells) were then collected and plated on
rat tail collagen-coated plates. For transient transfection
assays, after 4 h further culture, non-adherent (hemato-
poietic) cells were washed off with PBS, and remaining
hepatocytes were subjected to transfection as described
below. For RNA analysis, cells were cultured in the
presence or absence of 106 M all trans retinoic acid and
cultured for 6 h under normoxic or hypoxic conditions (1%
O2/5% CO2/94% N2). Hypoxic media was first sparged with
hypoxic gas before use, and CoCl2 was added at a
concentration of 104 M. After treatment, non-adherent
(hematopoietic) cells were removed by washing with PBS
before harvest, and RNA isolated from the remaining
adherent cells (hepatocytes).
DNA constructs
The wild type Epo promoter/enhancer Epo-LUC con-
struct, and the mDR2-Epo-LUC construct, were previously
described (Makita et al., 2001) as wtEpo-LUC and mutEpo-
LUC, respectively. Constructs containing the Epo gene
enhancer coupled to a basal HSV-TK promoter (Epo-TK-
LUC and variants) were made by subcloning the 96 bp
enhancer (Makita et al., 2001) into a polylinker site 5V of the
105 to +51 TK promoter obtained from pBLCAT2
(Luckow and Schutz, 1987). All mutations were introduced
by conventional site directed mutagenesis and confirmed by
sequencing. To mutate the HIF1 element, the wild type
sequence TACGTGC was changed to TGTACAT. The
Epo(TT)-LUC and Epo(TT)-TK-LUC reporter constructs
were made by converting the RAR half site sequence
TGACCT in the Epo enhancer DR2 element to TGTTCT.
Human receptor CMV promoter-based expression con-
structs were obtained from R. Evans and were appropriately
modified to make P-box mutations. HIF1a and ARNT
expression constructs were provided by G. Sememza and O.
Hankinson; GATA4 and FOG2 expression constructs were
provided by J. Molkentin and S. Tevosian.
Transient transfection assays
Hep3B cells were cultured in DMEM with 10% FBS and
plated on 12-well tissue culture plates. 1.2 Ag reporter
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transcription factor expression constructs were cotransfected
by lipofection (Invitrogen) under serum free conditions.
After 8–10 h incubation, the lipofection medium was
replaced with fresh 10% FBS containing DMEM with or
without 106 M all trans retinoic acid (Sigma), and cells
were incubated for 24 h before harvest. Primary hepatocytes
were cultured in 24-well plates; the total amount of DNA
used in transfection was half that described above for 12-
well plates. Calcium phosphate transfection was performed
for 16 h, followed by replacement with media with or
without 106 M all trans retinoic acid. Cells were further
incubated for 24 h. For luciferase analysis, cells were
harvested in lysis buffer and assayed with the Luciferase
Assay and Beta-Glo Assay Systems (Promega).Results
Differential Epo gene expression in fetal liver during
definitive erythropoiesis
In our previous study (Makita et al., 2001), we observed
that Epo transcript levels in fetal liver were approximately
10-fold reduced in RXRa mutants at E10 relative to normal
littermates, although by E12 the level of Epo expression was
equal in controls and mutants. The normalization of Epo
expression immediately precedes (by approximately 1 day)
the phenotypic recovery of erythroid differentiation in
mutant embryos. Our assumption was that normalization
of expression in mutant embryos occurred via the acquis-
ition of a new positive-acting transcriptional regulatory
program (such as HNF4), independent of retinoic acid and
RA receptors, that promoted elevated Epo gene transcription
beginning around E11.5–12.0. To test this assumption, we
recovered fetal liver RNA from control and RXRa mutant
embryos through the E10–13 period, and quantitatively
measured Epo transcript levels in a manner that allowed us
to compare Epo expression not only between controls and
mutants, but also between embryos at different develop-
mental stages. As shown in Fig. 1, we confirmed our earlierFig. 1. Expression of the Epo gene in fetal liver during definitive
erythropoiesis. Fetal liver tissue was isolated from wild type and littermate
RXRa-deficient embryos at the indicated stages, and quantitatively
analyzed as described in the Materials and methods section within the
linear range of amplification. 18S rRNA amplification ensures an equal
amount of input to each PCR reaction.observation that Epo expression in mutant embryos at E10 is
at least 10-fold lower than controls, whereas by E12 there is
equivalent expression between the two genotypes. However,
surprisingly, rather than there being a recovery (upregula-
tion) of Epo expression in mutant tissue, we instead
observed that Epo expression declines in normal embryos
during this interval, declining in fact to the basal and
constant level seen in RXRa-deficient embryos throughout
the E10–13 period. It should be noted that we measured
total fetal liver Epo expression in this analysis, normalized
to a per cell basis. During the E10–13 period, the total
number of fetal liver cells in wild type embryos increases
dramatically; however, this occurs through roughly equal
expansion of the hepatocyte and hematopoietic compart-
ments (for example, see below that the normalized fetal liver
expression of HNF4, a specific marker of hepatocytes, is
constant through this period). Thus, in normal embryos, the
per-hepatocyte expression of Epo declines dramatically
between E10 and E12. We infer that the relatively low
level of Epo expression seen from E12 onward is sufficient
to support erythroid differentiation in both normal and
RXRa-deficient embryos, although there is a specific
requirement for high level Epo expression at the onset of
fetal liver erythropoiesis (i.e., E9.5–11.5) that is mediated by
retinoic acid and RA receptors. The transient nature of the
fetal liver phenotype in RXRa mutant embryos, therefore,
reflects the temporally restricted requirement for RA
signaling during the E9.5–11.5 period, rather than a
transition to a new mode of gene regulation that promotes
high level Epo expression beginning around E12.
Declining level of retinoic acid signaling components
during fetal liver development
We next turned our attention to understanding the
regulatory components that support RA responsive regu-
lation of the Epo gene at E10, vs. RA-independent
expression at E12. We began by examining the expression
of all known components of retinoic acid signaling in the
fetal liver during the E10–13 period, including the retinoic
acid receptors, synthetic enzymes, degradation enzymes,
and cytoplasmic binding proteins. We also included analysis
of HNF4, as previous models held that HNF4 may regulate
Epo expression. For all genes, we evaluated total fetal liver
RNA levels by quantitative RT-PCR, and for the nuclear
receptors we also evaluated by Western blotting of fetal liver
nuclear extracts.
As shown in Figs. 2a–c, RXRa and HNF4a were
present at constant levels in the fetal liver throughout
midgestation. In contrast, the level of the three RARs varied
with liver maturation. All three RARs were present in E10
fetal liver; however, these levels decreased substantially by
E12, coincident with the time when regulation of Epo
expression becomes independent of RXR/RAR control.
RARh mRNA was 9-fold more abundant than RARa, and
25-fold more abundant than RARg, throughout the E10–13
Fig. 2. Expression profile of retinoic acid signal components during fetal liver development. (a, b, and c) Relative abundance of retinoic acid receptors and
HNF4 in fetal liver. Fetal liver samples were analyzed by (a) Western blot and (b, c) quantitative RT-PCR. (a) 15 Ag of nuclear extracts from fetal liver tissues
isolated from wild type embryos at the indicated developmental stages was analyzed by immunoblotting with indicated antibodies. The corresponding
Coomassie-stained gel is shown as a loading control. (b) Comparison of expression of the three RAR isotypes, RXRa, and HNF4a in fetal liver tissue isolated
from embryos at the indicated developmental stages. Note that the number of PCR cycles chosen for representation of each gene’s expression profile varies
because of difference in PCR amplification efficiency, such that signal cannot be compared between different genes. The primer pairs used recognize common
domains (i.e., not isoform-specific) of each gene. (c) Compiled representation of the relative prevalence of transcripts analyzed in three individual fetal liver
samples from three different litters at each of the developmental stages indicated, measured by quantitative PCR. Prevalences were calculated in arbitrary units
from each sample’s PCR amplification curve and amplification efficiency, and the mean F standard deviation was then normalized to the abundance of RXRa
at E10. The standard deviation of each sample may reflect variation between embryos, or because each sample was from a different litter, may also reflect small
differences in developmental stage. (d) Relative abundance of the two major isoforms of each RAR gene in fetal liver tissue from embryos at the indicated
developmental stage. (e and f) Relative abundance of retinoic acid synthetic and degradation enzymes in fetal liver. (e) Comparison of the four RALDHs and
three CYP26s. (f) Relative abundance of each mRNAwas calculated as in panel c, normalized to the prevalence of RXRa at E10. (g and h) Relative abundance
of retinoid binding proteins in fetal liver. (g) Comparison of the expression of the two CRBP and two CRABP genes in fetal liver tissue isolated from embryos
at the indicated developmental stage. (h) Relative abundance of each mRNAwas calculated as in panel c, normalized to the prevalence of RXRa at E10. All
RNA assays were conducted in the linear range of amplification (see Materials and methods).
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were expressed at negligible levels if detectable at all (data
not shown).
Each of the three RAR genes generates two major
transcripts through use of independently regulated pro-
moters (Leid et al., 1992). To identify the isoform-specific
expression pattern of the three RARs, we repeated the
quantitative RNA analysis using primer pairs that allowed
us to analyze both isoforms of each gene simultaneously
(Fig. 2d). RARh2 was the sole isoform of the RARh gene
expressed in the midgestation fetal liver, whereas both
RARa transcripts were present at approximately equal
levels, and RARg2 was approximately twice as prevalent
as RARg1.The declining levels of the RARs during the E10–12
period coincide with the time at which Epo expression
transitions from being RA- and RXRa-dependent to being
independent of RA. We therefore addressed mechanisms
that might account for the changing level of RAR
expression. In particular, the RARh2 promoter (which is
the most actively expressed in fetal liver) is regulated by
retinoic acid (Sucov et al., 1990). We hypothesized that the
declining level of retinoic acid receptor expression during
fetal liver development might be due simply to a declining
level of retinoic acid in the fetal liver. To evaluate this
model, we analyzed the expression of genes involved in
retinoic acid synthesis, degradation, and processing (Figs.
2e–h). In the E10 liver, expression of the RA synthetic
Fig. 3. Exogenous retinoic acid induces RARh2 but not Epo expression in
E12 fetal liver. (a) Comparison of Epo and of RAR isoforms as expressed in
fetal liver tissue from embryos at E12.0, isolated from pregnant wild type
females orally treated with 100 mg/kg retinoic acid for 0, 3, 6, and 9 h. (b)
Western blot analysis of the three RARs in E12.0 fetal liver nuclear extracts
prepared from embryos isolated from the same pregnant females as used in
panel a. The Coomassie-stained gel is shown as a loading control.
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expression of the cellular retinol binding protein CRBP1
and the two cellular retinoic acid binding proteins CRABP1
and CRABP2. Expression of all of these components then
declined as liver development progressed. RALDH3 and
CRBP2 were not expressed in the fetal liver, and expression
of the RA degradation enzymes was at marginal (Cyp26A1)
or undetectable levels (Cyp26B1 and C1). Curiously,
expression of RALDH4 increased rather than decreased
during this period of liver development, but only reached
prominent levels at E13. These results are consistent with
the early (E9.5–11.5) fetal liver having a relatively high
level of endogenous RA production, which decreases as
development progresses. In situ hybridization studies have
shown that RALDH2 is expressed specifically in coelomic
mesothelium that lines the outside of the liver (Abu-Abed et
al., 2002); the seemingly persistent high level of RALDH2
expression at E11 and E12 (Figs. 2e–f) may therefore not
result in high levels of RA inside the liver itself (see
Discussion). To a first approximation, then, the fetal liver
expression of RARs, and in particular the level of RA-
responsive RARh2, mirrors the expression patterns of the
RALDH synthetic enzymes and the CRBP and CRABP
binding proteins.
RA induces RARb2 but not Epo expression in E12.0
fetal liver
The results described above suggested that Epo gene
regulation might become RXRa- and retinoic acid-inde-
pendent in the later phase of fetal liver erythropoiesis (E12
and beyond) simply because of a low level of endogenous
retinoic acid production and thereby a consequent low level
of retinoic acid receptor expression. Previous studies have
demonstrated that RA treatment of pregnant female mice
induces RARh2 expression in a variety of tissues (Harnish
et al., 1990), and we confirmed that this occurred in E12
fetal liver as well, for both RNA and protein (Fig. 3).
Nonetheless, despite the elevation of RARh expression to
levels equivalent to that of E10 fetal liver, and the
provision of RA ligand to activate the receptor, Epo
expression in E12 fetal liver was nonresponsive to RA
treatment (Fig. 3a).
Epo gene expression is not regulated by HNF4 during fetal
liver erythropoiesis
HNF4 has been proposed as a regulator of Epo
expression, in part because of its expression pattern in fetal
liver and adult kidney, and in part because of its ability to
bind to the Epo enhancer DR2 element (Galson et al., 1995).
Indeed, in our previous study (Makita et al., 2001), we
suggested that the transition in regulation of Epo expression
from RXRa-dependence to RXRa-independence might
occur via the substitution of HNF4 activity for that of
RXR–RAR at the DR2 element. To address this modelgenetically, we utilized mice carrying a conditional allele of
HNF4a (Parviz et al., 2002), and crossed to lines in which
cre recombinase is expressed in the fetal liver; this strategy
was necessary because of the early lethality of conventional
HNF4a/ embryos (Chen et al., 1994). We first crossed to
a Meox2-cre line (Tallquist and Soriano, 2000); this line
drives recombination in the early epiblast, and thus results in
recombination of conditional target genes not only in the
fetal liver but throughout the embryo. Analysis of HNF4
transcripts indicated that recombination of the conditional
HNF4a allele was approximately 80% in E12.0 fetal liver
hepatocytes, and expression of the apolipoprotein B gene, a
hepatic gene known to be positively regulated by HNF4 (Li
et al., 2000), was reduced 4-fold compared to nonrecom-
bined controls (Fig. 4a). We also crossed the conditional
HNF4 allele against a transgene expressing cre recombinase
specifically in hepatocytes under the control of an albumin/
a-fetoprotein hybrid promoter (Parviz et al., 2003). Because
this transgene only drives sufficient cre expression to
promote relatively late target gene recombination, fetal
livers were isolated from embryos at E15.5 (Fig. 4b). At this
stage, hepatocyte HNF4a gene recombination was 90–95%,
which resulted in 5-fold reduction of Apo B gene
expression. In both cases, Epo expression was if anything
slightly higher (2-fold) in HNF4-deficient fetal liver rather
than lower, indicating that HNF4a is not a positive regulator
of Epo expression at this stage.
We also considered the possibility that HNF4a might be
competitive with RXR–RAR in terms of binding to the Epo
enhancer DR2 element. By treating with RA, and by
inducing RARh expression (Fig. 3), the now active RXR–
RAR complex might induce Epo expression if HNF4 were
no longer present to interfere with RXR–RAR access to the
enhancer. This model was not supported; we found that RA
treatment did not induce fetal liver Epo expression in
HNF4a-deficient embryos (Figs. 4a,b). Thus, we conclude
that HNF4 is not a positive activator of Epo expression in
Fig. 4. HNF4 does not regulate Epo gene expression during fetal liver
erythropoiesis. (a) Comparison of the abundance of HNF4, ApoB, and Epo
transcripts in fetal liver tissue from control (HNF4flox/flox) and mutant
(Meox2+/cre, HNF4flox/flox) embryos at E12.0. (b) Comparison of HNF4,
ApoB, and Epo expression in fetal liver tissue from control (HNF4flox/
flox) and mutant (albafp-cre, HNF4flox/flox) embryos at E15.5. Note that
recombination of the HNF4 allele results in a deleted but stable transcript;
the efficiency of cre-mediated excision of the HNF4 gene was not
complete, as indicated by the residual level of nonrecombined (floxed)
transcript relative to recombined (flox-out) HNF4 transcript present in these
samples.
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response of the Epo gene to RA treatment in E12 embryos.
All three RARs can interact with HIF1 and synergistically
regulate Epo gene regulation
Although RARh is inducible in fetal liver by RA
treatment, we considered the possibility that RARh might
not be able to transactivate the Epo enhancer. Although the
three RARs are highly homologous in their DNA binding
domains, their N-terminal and C-terminal sequences are
much more divergent, and in principle these domains could
encode unique transcriptional properties on certain target
genes that might not be shared between receptor subtypes.
To address this issue in transiently transfected cells is
complicated by endogenous expression of RARs. To
circumvent this complication, we generated reporter con-
structs containing the Epo enhancer sequence with several
types of modifications. These enhancer sequences were
assayed in the context of the native Epo promoter and in the
context of a heterologous thymidine kinase basal promoter,
following transient transfection into Hep3B hepatocarci-
noma cells, a cell line in which Epo expression is inducible
(Blanchard et al., 1992).
Erythropoietin expression is responsive to low oxygen
status, via a hypoxia response element that serves as a
binding site for the HIF1 transcription factor (Bunn et al.,
1998). The HIF1 binding site is located in the Epo enhancer
17 nucleotides from the retinoic acid responsive DR2
element (Pugh et al., 1991), and the two elementsobligatorily synergize in promoting high level expression
(Blanchard et al., 1992). The wild type Epo enhancer was
positively regulated by HIF1 (and by hypoxia; see below),
and further upregulated by retinoic acid treatment. Mutation
of either the HIF1 binding site or the DR2 element in the
Epo enhancer in the context of the Epo promoter abolished
expression; in the context of the heterologous TK promoter,
we observed much higher overall expression, such that a
modest hypoxic response was still observed when only the
DR2 element was mutated (Figs. 5a–b).
To address the ability of individual RARs to mediate
RA responsiveness on the Epo enhancer, a subtlely
mutated DR2 sequence that can be specifically recognized
by RAR variants containing compensatory mutations in
their DNA binding domains was employed. In the Epo
enhancer DR2 element (TGACCTctTGACCC), RXR binds
to the 3V half site (TGACCC) and RAR binds to the 5V half
site (TGACCT) (Rastinejad et al., 1995). Reporter con-
structs in which the RAR half site was mutated by two
nucleotides (i.e., TGTTCTctTGACCC) were identical in
the abrogation of transcriptional response to hypoxia and
retinoic acid as were constructs with more extensive DR2
element mutations (e.g., compare Figs. 5c–d to the mDR2
constructs of Figs. 5a–b). Thus, endogenous receptors are
unable to recognize elements with this 2 nucleotide
mutation.
We next introduced RAR expression constructs in
which the DNA binding domains were altered to be able
to recognize the mutated DR2 element described above.
The domain of nuclear receptors that is responsible for
DNA half site sequence recognition is called the P-box,
and all three RARs have an identical sequence in this
domain (CEGCKG). Previous studies (Umesono and
Evans, 1989) have demonstrated that substitution of the
P-box of the retinoic acid receptor with that of the
glucocorticoid receptor (CGSCKV) was sufficient to
change response element specificity from the RAR half
site (TGACCT) to that of the glucocorticoid receptor
(TGTTCT), such as was introduced into the 2 bp mutated
DR2 element described above. We therefore made gluco-
corticoid receptor-type P-box substitutions of all three
RARs, and cotransfected these individually with the
corresponding mutated reporter construct. This approach
utilizes endogenously expressed RXRs, but is independent
of endogenous RARs. We found that all three P-box
mutated RARs are able to support high level activation of
reporters with the mutated DR2 element, both in terms of
RA response as well as for interaction with HIF1 in
promoting hypoxic response. Thus, RARh is competent for
transcriptional activation of Epo gene expression, and by
virtue of its abundance, RARh is the presumed primary
mediator of RA activation of Epo expression in E9.5–11.5
fetal liver tissue. The inability of RA treatment to induce
Epo expression in the E12 fetal liver, even when RARh is
induced (Fig. 3), is therefore not for lack of a suitably
active receptor.
Fig. 5. All three RARs can synergize with HIF1 to activate the Epo enhancer. Reporter constructs containing the wild type Epo gene enhancer or versions
mutated in the DR2 or HIF1 elements were coupled to the native Epo promoter (a, c) or to a heterologous TK promoter (b, d). (a, b) Reporter genes were
cotransfected with RXRa and RARa expression plasmids into Hep3B cells, without or with cotransfection of HIF1 (HIF1a and ARNT), and cultured under
normoxic conditions in the absence or presence of 106 M all trans retinoic acid. WT, mDR2, and mHIF1 refer to variants of the Epo-LUC and Epo-TK-LUC
reporters. (c, d) The indicated reporter genes (Epo(TT)-LUC and Epo(TT)-TK-LUC) were transfected into Hep3B cells without or with cotransfection of HIF1
under normoxic conditions in the presence or absence of 106 M all trans retinoic acid, with cotransfected P-box mutated RAR expression plasmids as
indicated.
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We next considered whether HIF1 activity and tissue
hypoxia might explain the lack of response of Epo
expression to retinoic acid in E12 fetal liver. We assessed
hypoxic status in two independent ways, both of which gave
equivalent results. First, we immunostained for the presence
of HIF1a in fetal liver tissue sections of embryos through
the E10–13 period. HIF1a is transcribed and translated
regardless of oxygen tension; however, translated protein
fails to accumulate under normoxic conditions via rapid
proteosomal degradation (Semenza, 2001). Under hypoxic
conditions, HIF1a protein is stabilized and heterodimerizes
with HIF1h to effect nuclear gene expression. Second, we
treated pregnant female mice with pimonidazole hydro-
chloride, which forms adducts with thiol groups in proteins,
peptides, and amino acids under low oxygen conditions that
are specifically detectable by immunohistochemistry. This
compound is established to be useful for visualizing hypoxia
in vivo, both in adult animals (Samoszuk et al., 2004) and inembryos (Lee et al., 2001). As shown in Fig. 6, both
methods revealed comparable regions of the embryo that are
hypoxic. Specifically, addressing fetal erythropoiesis, this
analysis revealed strong signal in the fetal liver of E10
embryos, although by E11 this pattern had become weaker
and more diffuse, and was mostly negative at E12. Other
tissues of the embryo showed somewhat different patterns:
most tissues were positive at E10, whereas the brain, dorsal
root ganglia, and parts of the heart remained positive at E11
and E12. In general, RXRa/ embryos showed sustained
and widespread tissue hypoxia compared to wild type
embryos at E11 and E12; this may reflect placental defects
in this mutant background (see Discussion) that might result
in less efficient placental gas exchange. Importantly, the
period of highest Epo expression in the fetal liver (E9.5–
10.5) coincides with the time when this tissue is most
hypoxic. As observed above, retinoic acid receptors and
HIF1 collaborate to support high level Epo expression.
Therefore, in E12.5 embryos, even in the presence of
exogenous retinoic acid (and the consequent high level of
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would be sufficient to prevent induction of the Epo gene.
Retinoic acid and hypoxia do not induce Epo expression in
E12 primary hepatocytes
We next examined Epo mRNA levels in cultured primary
hepatocytes isolated from embryos at E12.0 after exposure
to both hypoxia and retinoic acid. Retinoic acid treatment
induced RARh2 (and to a lesser extent RARg2) expression
in these cells under both normoxic and hypoxic conditions;
nonetheless, Epo mRNA was not induced by hypoxia and
retinoic acid treatment (Fig. 7a).Fig. 6. Transient hypoxia during fetal liver development. Immunohistochemical
littermate RXRa/ embryos isolated at E10–E12 as indicated. Immunoreactive tis
panel points to the fetal liver, which is shown at higher magnification in the panWe then tested reporter gene activity in primary
hepatocytes isolated from embryos at E12.5, again using
constructs containing the Epo 3V enhancer in conjunction
with the native Epo promoter or with a heterologous TK
basal promoter. We found robust induction of Epo/TK-LUC
reporter activity by retinoic acid treatment in presence of
overexpressed HIF1 in E12 primary hepatocytes, and in a
manner that required the integrity of the DR2 and HIF1
elements (Fig. 7b), mirroring the behavior of this construct
in Hep3B cells (Fig. 5b). However, a different result was
obtained when the Epo enhancer was tested in conjunction
with the Epo promoter in primary E12 hepatocytes (Fig. 7c).
The Epo promoter/enhancer reporter construct (Epo-LUC)detection of HIF1a protein and pimonidazole adducts in wild type and
sue is visualized as dark brown (DAB-positive) staining. The arrow in each
el to the right of each pair.
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unlike in Hep3B cells (Fig. 5a), retinoic acid was unable to
further induce this reporter gene in E12 primary hepato-
cytes. These results demonstrate a significant difference
between the Epo promoter and the TK promoter in terms ofFig. 7. Retinoic acid induction of Epo expression in E12 primary hepatocytes requ
acid receptors but not Epo expression in E12 primary hepatocytes. Expression of
normoxic (20% O2) or hypoxic (1% O2) conditions in the absence or presence of 10
on the Epo enhancer in the context of a heterologous TK promoter in E12 primary h
the Epo promoter requires GATA factors. E12 hepatocytes were transfected w
treatments were as in panel b. (d) Expression of GATA4, GATA6, and FOG2 in fe
wild type and littermate RXRa-deficient embryos at the indicated stages, and qusynergy with the Epo enhancer, and in terms of promoting
high level expression in response to retinoic acid and
hypoxia: the TK promoter is permissive in both cell types,
whereas the Epo promoter is active in Hep3B cells but is
markedly less so in E12 hepatocytes.ires HIF1 and GATA factors. (a) Retinoic acid and hypoxia induce retinoic
Epo and of the RAR isoforms in cultured primary E12 hepatocytes under
6 M retinoic acid for 6 h is shown. (b) Retinoic acid and hypoxia synergize
epatocytes. (c) Retinoic acid induction of the Epo enhancer in the context of
ith RXR/RAR and/or GATA4/FOG2 expression constructs as indicated;
tal liver during definitive erythropoiesis. Fetal liver tissue was isolated from
antitatively analyzed.
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requires GATA factors
Recently, the zinc finger transcription factor GATA4 was
identified as a positively-acting factor regulating Epo gene
expression in Hep3B cells (Dame et al., 2004). GATA4 acts
via a binding site in the proximal promoter of the Epo gene,
and is a member of a multigene GATA protein family. Thus,
we considered if there was any correlation between GATA
function and the activity of the Epo promoter in E12
hepatocytes. Surprisingly, GATA4 and GATA6 expression
was strikingly similar to that of Epo expression pattern in
wild type fetal liver, being highly expressed at the onset of
fetal liver erythropoiesis and declining thereafter (Fig. 7d).
The GATA cofactor FOG2 was also expressed in a similar
pattern. GATA4, GATA6, and FOG2 were normally
expressed in the absence of RXRa, and are thus clearly
not responsible for the fetal liver phenotype of RXRa/
embryos. GATA4 and GATA6 are abundantly expressed in
Hep3B cells (Dame et al., 2004), although not in E12
hepatocytes (e.g., Fig. 7d and data not shown). Transfection
assays (Fig. 7c) demonstrated that forced expression of
GATA4 and FOG2 was sufficient to convert the responsive-
ness of the Epo promoter/enhancer reporter construct in
primary E12 hepatocytes to that seen in Hep3B cells
(compare to Fig. 5a). Thus, the combined activities of
GATA, HIF1, and RXR/RAR are required for full expres-
sion of the Epo gene. All three components are present and
active in the E10 fetal liver, and none are present by E12.
Expression of GATA factors in E12 hepatocytes, combined
with RA and hypoxia treatment, is sufficient to permit high
level Epo expression in E12 hepatocytes as occurs in E10
hepatocytes and in E10 fetal liver.Discussion
Epo and erythropoietic differentiation in the fetal liver
In the fetal liver, the onset of Epo gene expression at
E9.5 coincides with the immigration of hematopoietic
stem cells from the nearby aortic–gonadal–metanephros
(AGM) region (Medvinsky and Dzierzak, 1996), and is
responsible for maintaining erythroid progenitor cell
survival and promoting differentiation along the erythro-
poietic pathway (Wu et al., 1995). Our previous work
demonstrated that early Epo expression is dependent on
RXRa gene function, and that the Epo gene is a direct
target for RA receptor transactivation (Makita et al.,
2001). This requirement is restricted to the E9.5–11.5
period, following which Epo expression becomes inde-
pendent of RXRa and retinoic acid function, and Epo
expression in mutant embryos becomes equal to that in
normal embryos. RXRa/ embryos are not globally
compromised in their development through this period
because sufficient numbers of yolk sac-derived primitiveerythrocytes persist and presumably sustain oxygen
delivery at adequate levels. From E12 onward, as
primitive erythrocytes become limiting, new red blood
cell differentiation is required for embryo viability. Indeed,
Epo/ mouse embryos die around E13.5 (Wu et al.,
1995), although the normal level of Epo expression in
RXRa/ mutants from E12 supports resumption of
erythropoiesis and embryo viability.
Our earlier model (Makita et al., 2001) suggested that the
transition from RXRa-dependent to RXRa-independent
control of Epo expression, around E11–12, occurred via
compensatory substitution of HNF4 transcriptional activity
on the Epo gene enhancer DR2 element. Our current
evidence demonstrates that HNF4 has no apparent role in
regulating fetal liver Epo expression. First, expression of
HNF4 does not change in a way that might reflect the onset
of transcriptional control in the E12 liver. More importantly,
our direct manipulation of HNF4 levels by conditional gene
mutation indicated no positive role in controlling Epo
expression. In fact, because Epo expression increases
slightly (2-fold) in HNF4a-deficient fetal liver, our results
would be more consistent with an inhibitory role if at all,
perhaps by displacement of other positive-acting factors
from the DR2 element. Previous studies in which HNF4
appeared to support Epo expression relied on transient
transfection and overexpression, and may therefore have
been misleading. We cannot say whether HNF4 has any
direct role in Epo expression in the adult kidney, as has also
been proposed; it would be necessary to undertake similar
conditional gene knockout in that tissue to address this
issue.
Our revised model suggests a different view of Epo gene
expression and of the molecular components that control
this expression. Retinoic acid and RA receptor function are
clearly required for high level Epo expression in the E9.5–
11.5 period. However, the level of Epo expression in
normal liver at E12 is not only equal to that of RXRa/
embryos at the same stage (as shown in our previous
study), but also equal to that of RXRa/ embryos at E10
(Fig. 1). Thus, the recovery in fetal liver phenotype and in
erythropoietic differentiation in RXRa/ embryos does
not occur through the activity of some new factor
supplanting the role of RXR–RAR on the Epo enhancer
DR2 element, but rather because expression of the Epo
gene becomes enhancer-independent, and a normal and
sufficient level of Epo expression persists in mutant tissue
to support erythropoietic differentiation at E12, although
clearly not at E10.
We cannot currently explain the requirement for the
approximately 10-fold higher level of Epo expression in the
E10 fetal liver relative to E12 and later. Although Epo has
been suggested to possibly have a homing (chemotactic)
role (Anagnostou et al., 1990; Gotoh et al., 1997), our
previous study demonstrated a normal number of erythroid
progenitors in RXRa-deficient fetal liver tissue (Makita et
al., 2001). We infer that Epo serves in its more conventional
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survival and promotes erythroid differentiation, although
the quantitative requirement for Epo expression clearly
differs between the two stages. One possible explanation
might lie in the growing size and cell number of the fetal
liver during the E10–13 period. Although Epo expression
on a per cell basis declines in normal embryos (Fig. 1; this
is a per cell measurement because Epo mRNA was
measured relative to 18S rRNA), the total level of Epo
expression per fetal liver is maintained. Thus, a low level of
expression per hepatocyte in the E12 liver might be
sufficient to promote efficient erythropoietic differentiation,
given the increasing number of hepatocytes present, relative
to the small number of hepatocytes present at the onset of
definitive erythropoiesis at E10. The utilization of retinoic
acid and RA receptors to boost Epo expression during the
E9.5–11.5 period may have evolved specifically to accom-
modate the low number of Epo-expressing cells present at
that time.
Molecular mechanisms controlling Epo gene expression
Our results indicate that three independent components
together account for high level Epo expression in the early
(E10) fetal liver: retinoic acid and its receptors, HIF1, and
GATA factors. Indeed, all three are essential: absence of
RXRa results in decreased Epo expression and in eryth-
ropoietic deficiency in vivo, absence of GATA factors (i.e.,
as in E12 primary hepatocytes) results in a lack of response
to the combined effect of hypoxia plus retinoic acid, and the
Epo gene is refractory to retinoic acid and RA receptors
even in the presence of GATA4/FOG2 (e.g., in Hep3B cells)
when cells are normoxic.
We demonstrated in this study that retinoic acid
production was more active in the early fetal liver and
declined subsequently. Retinoic acid levels are controlled
primarily through expression of the retinoic acid synthetic
and degradation enzymes, the latter appears to be incon-
sequential in fetal liver biology. In fetal liver development,
RALDH1 expression is observed in the liver mass
(Niederreither et al., 2002), whereas RALDH2 expression
is restricted to the coelomic epithelium surrounding the
developing liver (Abu-Abed et al., 2002). Hepatoblasts in
the E10 liver are presumably activated by RA from the
coelomic epithelium (expressing RALDH2) which diffuses
inwards and from endogenous expression of RALDH1. By
E12, however, RALDH1 expression is mostly eliminated,
and the expanding volume of the liver would minimize the
extent to which RA produced in the coelomic epithelium
could diffuse inward to activate gene expression. Indeed, the
decreasing abundance of the RA-responsive RARh2 tran-
script suggests a minimal level of RA-induced gene
expression by E12 (Fig. 2).
Our model of RA regulation of early Epo expression was
predicated on the assumption that RXRa was the key RXR
serving as the heterodimeric partner for RARs in the fetalliver at this time. Indeed, our measurements indicate that
RXRh and RXRg are expressed at levels far lower than
RXRa in the fetal liver, and that absence of RXRa is
consistent with abrogation of RA responsiveness. All three
RARs are present in the fetal liver throughout the E10–13
period, although RARh (specifically RARh2) is clearly the
most abundantly expressed. Nonetheless, absence of RARh
(all isoforms) in mouse embryos does not result in any
apparent fetal liver phenotype (data not shown), suggesting
that the other RARs can functionally support Epo expres-
sion in the absence of RARh. Indeed, using P-box mutant
receptor constructs (Figs. 5c–d), we showed that all three
RARs are able to interact with the transcriptional machinery
assembled at the Epo promoter and induce Epo reporter
constructs when bound at the enhancer DR2 element.
Hypoxia is a clearly established inducer of Epo
expression, via the HIF1 response element in the Epo
enhancer (Bunn et al., 1998). Our results indicate that the
early (E9.5–11.5) fetal liver is hypoxic, although not
thereafter. We note that a functional placental circulation
is established in mouse embryos around E11 (Adamson et
al., 2002), thereby bringing oxygen-rich blood into fetal
tissues. Thus, our measurement of the hypoxic status of the
fetal liver correlates well with the developmental anatomy
of embryonic circulation, and with the pattern of Epo
expression in the fetal liver.
Placental defects, specifically of the labrynthine layer,
have been described in RXRa/ embryos (Sapin et al.,
1997). Our results demonstrate that the fetal liver of mutant
embryos is persistently hypoxic at E11.5 and E12.5,
presumably because of inefficient placental function. None-
theless, this condition does not result in elevated Epo
expression, primarily because retinoic acid responsiveness is
absent (for lack of RXRa). This again demonstrates the
synergistic role of HIF1 and RXR/RAR in supporting high
level Epo expression.
Several GATA factors are expressed in the fetal liver, and
in various cell types of the fetal liver. There is a suggestion
from previous studies that GATA4 and GATA6 may be
retinoic acid regulated (Arceci et al., 1993; Zhuang et al.,
2003); however, our observations indicate that these genes
are expressed at normal levels in RXRa/ embryos (Fig.
7d). GATA4 is expressed in Hep3B cells and there is
evidence of GATA4 expression in fetal hepatocytes (Dame
et al., 2004), although recent studies (S.A.D., unpublished
observations) have concluded instead that GATA4 is
expressed primarily by endothelial and sinusoidal cells of
the fetal liver. Even if so, the observation that GATA4
cotransfection was required to achieve high level Epo gene
reporter activity indicates that the endothelial and sinusoidal
cells (i.e., GATA4-positive) do not express Epo. We used
GATA4 in our transfection studies as an exemplar of all
GATA factors; however, other GATA factors, such as the
highly homologous GATA6 which is clearly expressed in
hepatoblasts (Nemer and Nemer, 2003), may be the primary
regulators of Epo expression in the fetal liver.
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E11.5. In this study, we have focused on processes that
mediate Epo gene expression, but it is obvious that these
processes must be interrelated with other events that are
underway at this time. In particular, around E11.5,
hepatoblasts are in the process of differentiating to
hepatocytes, with an associated reconfiguration of gene
expression. Expression of many of the genes involved in
high level Epo expression at earlier stages declines
beginning around E11.5, including that of the RARs,
RALDHs, CRBPs, and CRABPs, whereas many genes
associated with mature hepatocyte function (e.g., metabo-
lism, transport, etc.) are first expressed at this time. To the
extent that high level Epo expression is necessary in the
E9.5–11.5 period, but not beyond, the timing of liver
maturation (and the consequent reduction in expression of
Epo regulatory components) must be coordinated; the
alleviation of hypoxia associated with the onset of placental
circulation may be one trigger for hepatoblast differentia-
tion. In any event, this is temporally coordinated to occur
once the need for high level Epo expression has passed, and
once the regulatory components that support early high level
Epo expression–retinoic acid and its receptors, hypoxia/
HIF1, and GATA factors–are therefore no longer needed.Acknowledgments
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